Newsroom

News

For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a joint venture of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University (JMU) Würzburg, now demonstrate a new way to study CRISPR systems that can accelerate their conversion into tools. Their approach was published today in the journal Molecular Cell.

24.02.2022

HIRI

News

Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models.

18.02.2022

HZI Campus

News

An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School, describes the dual effect of the endogenous substance itaconic acid, which is both antiviral and anti-inflammatory. Their study, which has now appeared in the journal PLoS Pathogens, opens up perspectives for possible therapeutic applications of itaconic acid against severe courses of disease in viral infections.

17.02.2022

HZI Campus

TWINCORE

Fruchtkörper von Myxobakterien unter dem Lichtmikroskop

News

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections. Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof Rolf Müller and Prof Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr Thomas Hesterkamp and Evotec. The HIPS is a site of the HZI in collaboration with Saarland University.

04.02.2022

HZI Campus

HIPS

News

The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially in combating the SARS-CoV-2 pandemic, and the future development of infection research in Lower Saxony. He also delivered a message of thanks to the scientists at the research centre in Braunschweig.

04.02.2022

HZI Campus

News

Viruses are mostly encountered as pathogens. However, virus-based vaccination platforms can also help to provide protection from different diseases. In a mouse model, researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig together with national and international partners including the German Center for Infection Research (DZIF), the German Primate Center – Leibniz Institute for Primate Research (DPZ), the Technische Universität Braunschweig and the University of Rijeka, Croatia, have developed a novel cytomegalovirus-based vaccine against different respiratory viruses. A single dose of the vaccine that consists of a cytomegalovirus that incorporates genes from coronavirus or influenza A efficiently protected mice from the respiratory infections. The results on the vaccine candidate, which is not yet market-ready, were published in the journal Cellular & Molecular Immunity.

17.01.2022

HZI Campus

Back to the first page
...
41
42
43
44
...
145

HZI in the media

... er Klinischer Direktor des Helmholz Zentrums für Infektionsforschung (HZI) und Gründungsdirektor des Zentrums für Individualisierte ...

21.08.2025

Deutsche Gesellschaft für Innere Medizin e.V.

Nature Medicine

. The CiiM is a joint institution of the Helmholtz Center for Infection Research (HZI) and Hannover Medical School (MHH).

21.08.2025

Medical Xpress

und damit einhergehenden Erkrankungen zu sein.“

Helmholtz-Zentrum für Infektionsforschung

Originalpublikation:

J. Botey-Bataller, N. van

21.08.2025

Verband Deutscher Biologen e.V.

Now, a team of researchers, led by scientists from the Helmholtz Centre for Infection Research in Germany, has reported that a gene in the

21.08.2025

The Hindu

Cicin-Sain, a viral immunologist at Germany's Helmholtz Centre for Infection Research, is leading the development of a respiratory syncytial

16.08.2025

The Times of India

Instituts für Pharmazeutische Forschung Saarland (HIPS), einem gemeinsamen Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) ...

15.08.2025

Springer Medizin

... Einrichtung betreiben die MHH und das Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig gemeinsam.

In seine ...

15.08.2025

Neue Presse (Hannover)

Medicine Bundesamt für Verbraucherschutz und Lebensmittelsicherheit Helmholtz-Zentrum für Infektionsforschung ARD alpha Universität Würzburg

13.08.2025

Brisant

... Prof. Dr. rer. nat. Dunja Bruder, Helmholtz-Zentrum für Infektionsforschung, Braunschweig und Institut für Med. Mikrobiologie ...

12.08.2025

Deutsches Ärzteblatt

Register now for the HZI-Newsletter

and stay up to date!

Email address

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.

Please enter here the word as displayed in the picture. This is to prevent spamming.*

If you can't read the word, click here.